

Subscriber access provided by ISTANBUL TEKNIK UNIV

# 6-O-Benzoylgomisin O, a New Lignan from the Fruits of Schizandra chinensis

Chien-Chih Chen, Chien-Chang Shen, Yi-Zen Shih, and Tsu-Ming Pan

J. Nat. Prod., 1994, 57 (8), 1164-1165• DOI: 10.1021/np50110a006 • Publication Date (Web): 01 July 2004

Downloaded from http://pubs.acs.org on April 4, 2009

# More About This Article

The permalink http://dx.doi.org/10.1021/np50110a006 provides access to:

- Links to articles and content related to this article
- Copyright permission to reproduce figures and/or text from this article



Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

## 6-0-BENZOYLGOMISIN O, A NEW LIGNAN FROM THE FRUITS OF SCHIZANDRA CHINENSIS

CHIEN-CHIH CHEN,\* CHIEN-CHANG SHEN,

National Research Institute of Chinese Medicine, 2 Lane 391, Pei-I Rd. Sec. 2, Hsintein, Taipei Hsien, Taiwan, Republic of China

YI-ZEN SHIH, and TSU-MING PAN

Research Institute of Applied Chemistry, Chinese Cultural University, Taipei, Taiwan, Republic of China

ABSTRACT.—A new dibenzocyclo-octadiene lignan, 6-0-benzoylgomisin O[1] was isolated from the fruits of *Schizandra chinensis* together with 5-hydroxymethyl-2-furaldehyde, protocatechuic acid, and sorbic acid. The structure of 1 was determined by spectral analysis.

The fruits of Schizandra chinensis Baill. (Schizandraceae) have been used as a tonic and an anti-aging drug in traditional Chinese medicine (1). Sesquiterpenoids (2,3) and lignans (4-12) have been isolated from this drug. Our previous studies have demonstrated that gomisin A, gomisin B, and schizandrin isolated from this drug exhibited Ca<sup>++</sup>-antagonistic activity on the guinea pig taenia coli (13). In our continuing research on this drug, a new lignan, 6-0-benzoylgomisin O[1], and three known compounds, 5hydroxymethyl-2-furaldehyde (14), protocatechuic acid, and sorbic acid, were isolated from S. chinensis. This paper describes the isolation and structural elucidation of the new lignan 1.

The ir spectrum of 1 indicated that it is a dibenzocyclo-octadiene lignan (4-12) possessing a benzoyloxy group (1715 cm<sup>-1</sup>). The cd spectrum indicated that the compound has an S-biphenyl configuration (5, 12, 15). The <sup>1</sup>H-nmr spectrum showed the presence of two secondary methyls ( $\delta$  0.83 and 0.99, doublet for each), a benzylic methylene ( $\delta$  2.19– 2.28), and a benzylic methine ( $\delta$  5.92) with a benzoyloxy group. A methylenedioxy moiety ( $\delta$  5.89), two aromatic protons ( $\delta$  6.47 and 6.74) and four methoxyls (§ 3.51, 3.55, 3.86, and 3.89) were also associated wth the aromatic rings. The <sup>1</sup>H-nmr spectral data of **1** were very similar to those published for gomisin O [2] (6) except for the presence of five aromatic

protons ( $\delta$  7.27–7.62) and a benzylic methine proton at  $\delta$  5.92 (d, J=7.5 Hz), which indicated that the benzoyloxy group is linked at C-6 in this compound.

When the <sup>13</sup>C-nmr spectrum of 1 was compared with those of 2 and epigomisin O (7), which possess a boat conformation and twist-boat-chair conformation of the cyclo-octadiene ring respectively, the data of 1 exhibited a closer similarity to those of 2, especially at C-17 and C-18.

Finally, the structure of **1**, including the conformation of the cyclo-octadiene ring, was confirmed by nOe measurements as shown in Figure 1. Irradiation of H-4 at  $\delta$  6.74 enhanced the signals at  $\delta$ 3.89 (OCH<sub>3</sub>-3) and 5.92 (H-6) by 6% and 8%, respectively. Irradiation of H-11 at  $\delta$  6.47 did not affect the signals of any methoxyl group. Irradiation of the methyl groups at  $\delta$  0.99 and 0.83 en-




FIGURE 1. NOe Observations for 1.

hanced the signal at  $\delta$  5.92 (H-6) by 2% and 4%, respectively.

On the basis of the above results, the structure of 6-0-benzoylgomisin O was assigned as 1, with a boat conformation of the cyclo-octadiene ring.

### **EXPERIMENTAL**

GENERAL EXPERIMENTAL PROCEDURES.—The ir spectra were recorded on a Biorad Ft-ir spectrometer. The cd spectrum was recorded using a Jasco-710 CD polarimeter. <sup>1</sup>H- and <sup>13</sup>C-nmr spectra were taken on a Bruker AM-300WB (300 MHz) Ft-nmr instrument. Hreims and eims were obtained on JEOL SX-102A and JEOL JMS-HX100 spectrometers, respectively. Protocatechuic acid and sorbic acid were purchased from Sigma Chemical Company.

PLANT MATERIAL.—The fruits of Schizandra chinensis were purchased from a market in Taipei, under the direction of Mr. M.T. Kao, National Research Institute of Chinese Medicine, where voucher specimens are maintained.

EXTRACTION AND ISOLATION .- The ground fruit materials (3 kg) were extracted with 95% EtOH and the extract was concentrated in vacuo and fractionated into EtOAc- and MeOH-soluble fractions. The EtOAc-soluble fraction was chromatographed on a Si gel column. The following fractions were eluted in order with the indicated solvent system: fraction 1 [n-hexane-EtOAc (30:1)], fraction 2 [n-hexane-EtOAc (20:1)], fraction 3 [n-hexane-EtOAc (10:1)], fraction 4 [nhexane-EtOAc (2:1)], and fraction 5 (Me<sub>2</sub>CO). Repeated chromatography of fraction 4, first by cc [Si gel, n-hexane-Me<sub>2</sub>CO (8:1)] and then by hplc [Cosmosil 5C-18Ar, 8×250 mm; CH<sub>3</sub>CN-H<sub>2</sub>O (7:3), 2 ml/min], gave 1 (10 mg). Fraction 5 was further chromatographed on a Si gel column with CHCl<sub>3</sub>-Me<sub>2</sub>CO (4:1) to yield 5-hydroxymethyl-2furaldehyde, protocatechuic acid, and sorbic acid.

6-O-Benzoylgomisin 0 [1]. - Amorphous powder;  $[\alpha]^{25}D = -41.39^{\circ}$  (c=1.06, CHCl<sub>3</sub>); cd  $\Delta \epsilon$ (MeOH) (nm) -2.74 (203.1), +2.47 (222.5), -1.24 (242.0), -0.56 (250.2), -0.31 (255.8), +0.51 (270.0); ir v max (KBr) 1715, 1699, 1614, 1590, 1274, 1110 cm<sup>-1</sup>; eims m/z 520 (M<sup>+</sup>, 100), 398 (42), 105 (68), 77 (24); hreims m/z 520.2092  $(calcd for C_{30}H_{32}O_8, 520.2097); {}^{1}H nmr(CDCl_3)\delta$ 0.83 (3H, d, J=6.9 Hz, 8-CH<sub>3</sub>), 0.99 (3H, d, J=6.9 Hz, 7-CH<sub>3</sub>), 2.02–2.15 (2H, m, H-7 and H-8), 2.19-2.28 (2H, m, H-9), 3.51 (3H, s, -OCH<sub>3</sub>), 3.55 (3H, s, -OCH<sub>3</sub>), 3.86 (3H, s, 2-OCH<sub>3</sub>), 3.89 (3H, s, 3-OCH<sub>3</sub>), 5.89 (2H, s, -OCH<sub>2</sub>O-), 5.92 (1H, d, J=7.5 Hz, H-6), 6.47 (1H, s, H-11), 6.74 (1H, s, H-4), 7.27-7.62 (5H, m, Ph-CO-);  ${}^{13}C$  nmr (CDCl<sub>3</sub>)  $\delta$  14.2 (C-18), 19.2 (C-17), 36.5 (C-8), 36.8 (C-9), 37.5 (C-7), 55.9 (OCH<sub>3</sub>), 59.0 (OCH<sub>3</sub>), 60.5 (OCH<sub>3</sub>), 60.8 (OCH<sub>3</sub>), 81.5 (C-6), 100.6 (OCH<sub>2</sub>O), 102.4 (C-11), 110.6 (C-4), 121.7 (C-15), 123.1 (C-16), 132.2 (C-13), 134.4 (C-10), 135.4 (C-5), 141.8 (C-14 and C-2), 148.7 (C-12), 151.7 (C-1), 152.0 (C-3), benzoyl moiety [127.9 (C-3' and C-5'), 129.6 (C-2' and C-6'), 130.3 (C-1'), 132.6 (C-4'), 165.4 (C=O)].

#### ACKNOWLEDGMENTS

We thank Dr. Shoei-Sheng Lee, School of Pharmacy, National Taiwan University, for measurement of the cd spectrum. This investigation was supported by a research grant from the National Science Council of the Republic of China (NSC82-0420-B-077-007-M03).

#### LITERATURE CITED

- 1. H.Y. Hsu and W.G. Peacher, "Chinese Herb Medicine and Therapy." Oriental Healing Arts Institute, Los Angeles, p. 176 (1976).
- Y. Ohta and H. Hirosa, Tetrabedron Lett., 1251 (1968).
- 3. Y. Ohta and H. Hirosa, Tetrabedron Lett., 2483 (1968).
- H. Taguchi and Y. Ikeda, Chem. Pharm. Bull., 23, 3296 (1975).
- Y. Ikeya, H. Taguchi, I. Yosioka, and H. Kobayashi, *Chem. Pharm. Bull.*, 27, 1383 (1979).
- Y. Ikeya, H. Taguchi, I. Yosioka, and H. Kobayashi, *Chem. Pharm. Bull.*, 27, 2695 (1979).
- Y. Ikeya, H. Taguchi, H. Sasaki, K. Nakajima, and I. Yosioka, *Chem. Pharm.* Bull., 28, 2414 (1980).
- 8. Y. Ikeya, H. Taguchi, and I. Yosioka, *Chem. Pharm. Bull.*, **28**, 2422 (1980).
- Y. Ikeya, H. Taguchi, I. Yosioka, and H. Kobayashi, *Chem. Pharm. Bull.*, 28, 3357 (1980).
- Y. Ikeya, H. Taguchi, I. Yosioka, Y. Iitaka, and H. Kobayashi, *Chem. Pharm. Bull.*, 27, 1395 (1979).
- Y. Ikeya, N. Ookawa, H. Taguchi, and I. Yosioka, *Chem. Pharm. Bull.*, **30**, 3202 (1982).
- Y. Ikeya, H. Taguchi, and I. Yosioka, *Chem. Pharm. Bull.*, **30**, 3207 (1982).
- C.C. Chen, Y.L. Huang, S.M. Chen, H.T. Chen, Y.P. Chen, and H.Y. Hsu, J. Taiwan Pharm. Assoc., 39, 255 (1987).
- S. Nishibe, S. Hisada, and I. Inagaki, *Chem. Pharm. Bull.*, **21**, 1155 (1973).
- Y. Ikeya, H. Taguchi, I. Yosioka, and H. Kobayashi, *Chem. Pharm. Bull.*, **26**, 3257 (1978).

Received 2 December 1993